Drug Resistance Updates
Volume 1, Issue 6 , Pages 377-388 , 1998

Anti-growth factor therapy for lung cancer

  • Daniel C. Chan

      Affiliations

    • Lung Cancer Program and Department of Medicine, University of Colorado Cancer Center, Denver, CO, USA
    • Carcinex Inc., Boulder, CO, USA
    • ,
  • Mark Geraci

      Affiliations

    • Lung Cancer Program and Department of Medicine, University of Colorado Cancer Center, Denver, CO, USA
    • ,
  • Paul A Bunn Jr

      Affiliations

    • Lung Cancer Program and Department of Medicine, University of Colorado Cancer Center, Denver, CO, USA
    • Corresponding Author InformationCorrespondence to: Paul A Bunn Jr MD, University of Colorado Cancer Center, Box B188, 4200 E 9th Ave, Denver, CO 80262, USA. Tel: 303-315-3007, Fax: 303-315-3004

Received 31 August 1998 ,Revised 9 October 1998 ,Accepted 12 October 1998.

References 

  1. Cook RM, Miller YE, Bunn PA. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer. 1993;17:69–141
  2. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985;316:823–826
  3. Cohen AJ, Bunn PA, Franklin W, et al. Variable expression in human lung inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996;56:831–839
  4. Shipp MA, Tarr GE, Chen C, et al. CD 10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. In: Proc Natl Acad Sci USA. 88:1991;p. 10662–10666
  5. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 1995;16:259–270
  6. Heasley LE, Zamarripa J, Storey B, et al. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase deficient Ga16. J Biol Chem. 1996;271:349–354
  7. Mitchell FM, Heasley LE, Qian NX, et al. Differential modulation of bombesin-stimulated phospholipase Cβ and mitogen-activited protein kinase activity by [D-Arg1, D-Phe5, D-Trp7,9, Leu11) substance P. J Biol Chem. 1995;270:8623–8628
  8. Jarpe MB, Knall C, Mitchell FM, et al. (D-Arg1, D-Phe5, D-Trp7,9,Leu11) Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem. 1998;273:3097–3104
  9. Woll PJ, Rozengurt EA. (D-Arg1, D-Phe5, D-Trp7,9, Leu11) substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. In: Proc Natl Acad Sci USA. 85:1988;p. 1859–1863
  10. Bunn PA, Chan D, Dienhart DG, et al. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res. 1992;52:24–31
  11. Bunn PA, Chan D, Stewart J, et al. Effects of neuropeptide analogs on calcium flux and proliferation in lung cancer cell lines. Cancer Res. 1994;54:3602–3610
  12. Nakanishi Y, Mulshine JL, Kasprzyk PG, et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988;82:354–359
  13. Vostrys M, Moran P, Seligman P. Transferrin synthesis by small-cell lung cancer cells acts as an autocrine regulator of cellular proliferation. J Clin Invest. 1988;82:331–339
  14. Reeve JG, Payne JA, Bleehen NM. Production of immunoreactive insulin-like growth factor-I (IGF-1) and IGF-1 binding proteins by human lung tumours. Br J Cancer. 1990;61(5):727–731
  15. Carpenter G, Cohen S. Epidermal growth factor. Ann Rev Biochem. 1983;48:193–216
  16. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984;307:521–527
  17. Yamamoto T, Kamata M, Kawano H, et al. High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res. 1986;46:414–416
  18. Kelley MJ, Linnoila RI, Avis IL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing patients with small cell lung cancer. Chest. 1997;112:256–261
  19. Fan Z, Masui H, Atlas F, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322–4328
  20. Bos M, Mendelsohn J, Bowden D, et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. In: Proc Am Soc Clin Oncol. 15:1996;p. 443
  21. Divigi CR, Welt S, Dris M, et al. Phase I and imaging trial of indium III-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Instit. 1991;83:97–104
  22. Falcey J, Pfister D, Cohen R, et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients with head and neck or lung carcinomas. In: Proc Am Soc Clin Oncol. 16:1997;p. 383a
  23. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53:4637–4642
  24. Layton JE, Scanlon DB, Soveny C, Morstyn G. Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res. 1988;48:4783–4789
  25. Trepel JB, Moyer JD, Cuttitta F, et al. A nobel bombesin receptor antagonist inhibits autocrine signals in a small-cell lung carcinoma cell line. Biochem Biophy Res Comm. 1988;156:1383–1389
  26. Bunn PA, Dienhart DG, Chan D, et al. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. In: Proc Natl Acad Sci USA. 87:1990;p. 2162–2166
  27. North WG, Fay MJ, Lango KA, Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifacited role for this neuropeptide. Cancer Res. 1998;58:1866–1871
  28. Sethi T, Herget T, Wu SV, Walsh JH, Rozengurt E. CCKA and CCKB receptors are expressed in small cell lung cancer cell lines and mediate CA2+ mobilization and clonal growth. Cancer Res. 1993;53:5208–5213
  29. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res. 1991;51:3621–3623
  30. Langdon SP, Sethi T, Ritchie A, et al. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vitro. Cancer Res. 1992;52:4554–4557
  31. VanderSpek JC, Sutherland JA, Zeng H, et al. Inhibition of protein synthesis in small cell lung cancer induced by the diphtheria toxin-related fusion protein DAB839 GRP. Cancer Res. 1997;57:290–294
  32. Shaw JP, Akiyoshi DE, Arrigo DA, et al. Cytotoxic properties of DAB486 EGF and DAB389 EGF, epidermal growth factor (EGF) receptor — targeted fusion toxins. J Biol Chem. 1991;51:21118–21124
  33. Pai LH, Gallo MG, FitzGerald DJ, Pastan I. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). Cancer Res. 1991;51:2808–2812
  34. Yamazaki H, Kijima H, Ohnishi Y, et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Nat Cancer Inst. 1998;90:581–587
  35. Lee CT, Wu S, Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 1996;56:3038–3041
  36. Bunn PA, Chan D, Helfrich B, et al. Recombinant neutral endopeptidase inhibits the in vitro and in vivo growth of human lung cancers with neuroendocrine features. Lung Cancer. 1997;18:147–149
  37. Bos M, Mendelsohn J, Kim Y, et al. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997;3:2099–2106
  38. Fathi Z, Way JW, Corjay MH, et al. Bombesin receptor structure and expression in human lung carcinoma cell lines. J Cell Bioch (Suppl). 1996;24:237–246
  39. Birch RM, Kyle DG. Mini-review: recent developments in the understanding of bradykinin receptors. Life Sci. 1992;50:829–838
  40. Chan D, Gera L, Helfrich B, et al. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharm. 1996;33:201–204
  41. Beckman A, Helfrich B, Bunn PA, Heasley LE. Expression of catalytically inactive phospholipase c beta disrupts phospholipase c beta and nitrogen-activated protein kinases signalling and inhibits small-cell lung cancer growth. Cancer Res. 1998;58:910–913
  42. Taylor SJ, Chae HZ, Rhee SG, Exton JH. Activation of the beta I isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature. 1991;350:516–518
  43. Prasad MV, Dermott JM, Heasley LE, et al. Activation of Jun kinase/stress-activated protein kinase of GTP-ase deficient mutants of G-alpha 12 and G alpha 13. J Biol Chem. 1995;270:18655–18659
  44. Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL. G alpha 12 and G alpha 13 stimulate Rho dependent stress fiber formation and focal adhesion assembly. J Biol Chem. 1995;270:24631–24634
  45. Kozasa T, Jiang X, Hart MJ, et al. p115 Rho GEF, a GTPase activating protein for G alpha 12 and G alpha 13. Science. 1998;280:2109–2111
  46. Hart MJ, Jiang X, Kozasa T. Direct stimulation of the guanine nucleotide exchange activity of p115 Rho GEF by G alpha 13. Science. 1998;280:2112–2114
  47. Viallet J, Sharoni Y, Frucht H, et al. Cholera toxin inhibits signal tranduction by several mitogens and the in vitro growth of human small cell lung cancer. J Clin Invest. 1990;86:1904–1912
  48. Butterfield L, Storey B, Maas L, Heasley LE. C-Jun NH2 -terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem. 1997;272:10110–10116
  49. Reeve JG, Bleehen NM. (D-Argl, D-Phe5, D-Trp7,9, Leu11) substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophy Res Comm. 1994;199(3):1313–1319
  50. Seckl MJ, Higgins T, Widmer F, Rozengurt E. (D-Arg1, D-Phe5, D-Trp7,9, Leu 11) substance P a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small-cell lung cancer cells. Cancer Res. 1997;57:51–54
  51. Chan D, Gera L, Helfrich B, et al. A new class of peptide antagonist dimers inhibits the growth of human lung cancer cells in vitro and in vivo. In: Proc Am Assoc. Cancer Res. 38:1997;p. 232
  52. Chan D, Gera L, Helfrich B, et al. Novel cytotoxic bradykinin antagonist dimers inhibit human lung cancer growth in vitro and in vivo. Lung Cancer. 1997;18(Suppl. 1):150
  53. Chan D, Helfrich B, Gera L, et al. Combination of peptide antagonist monomers and dimers enhances killing of human lung cancer cells. Lung Cancer. 1997;18(Suppl 1):149
  54. Chan D, Whalley E, Helfrich B, et al. Effect or linker length and type on the cytotoxic activity of Bradykinin antagonist dimers in human lung cancer cells in vitro. In: Proc Am Assoc Cancer Res. 37:1996;p. 417
  55. Chan D, Gera L, Helfrich B, et al. Novel cytolytic Bradykinin antagonist dimers inhibit human lung cancer growth. In: Proc Am Assoc Cancer Res. 37:1996;p. 417
  56. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides. 1985;6(2):161–164
  57. Cheronis JC, Whalley ET, Nguyen KT. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem. 1992;35:1563–1572
  58. Gera J, Stewart JM, Whalley ET, et al. A new class of potent bradykinin antagonist dimers. Immunopharmacology. 1996;33:178–182
  59. Whalley ET, Hanson HT, Stewart JM, Gera L. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physio Pharmacol. 1997;75(6):629–632
  60. Hock FJ, Wirth K, Albus U, et al. HOE-140 a new potent and long acting bradykinin antagonists. Br J Pharmacol. 1991;102:769–773
  61. Fisher ER, Faulson JD. A new in vitro cell line established from human large cell variant of oat cell lung cancer. Cancer Res. 1978;38:3830–3835
  62. Koros AM, Klein EC, Pan S, et al. Stability and utility fo the unique human small cell carcinoma SHP-77. Cancer Res. 1985;45:2725–2731
  63. Chan D, Chuang N, Jewett P, et al. Reversal of multidrug resistance by a dexniguldipine (B8509-035), niguldipine and verapamil in small cell lung carcinoma cell lines. In: Proc Am Assoc Cancer Res. 34:1993;p. 323
  64. Chan D, Helfrich B, Chuang N, et al. Syngerism of MDR modulators with adriamycin in non-selected multi-drug resistant lung cancer cells. In: Proc Am Assoc Cancer Res. 38:1997;p. 591
  65. Campling BG, Young LC, Baer KA, et al. Expression of the MRP and MDRI multidrug resistance genes in small cell lung cancer. Clin Cancer Res. 1997;3:115–122
  66. Roninson I. The role of MDR1 (Poglycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol. 1992;43:95–102
  67. Keizer H, Schuurhuis G, Broxterman HJ, et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 1989;49:2988–2993
  68. Kuiper CM, Broxterman HJ, Baas F, et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol. 1990;1:35–41
  69. Chou TC, Talalay PT. Quantitative analysis of dose-effects relationships: The combined effects of multiple drugs or enzyme inhibitions. Adv Enzyme Regul. 1984;22:27–55
  70. Oates JA, Fitzgerald GA, Branch RA, et al. Medical progress: clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med. 1988;319:689–698
  71. Smith WL. The eicosanoids and their biochemical mechanism of action. Biochemistry. 1989;259:315–324
  72. Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. In: Proc Natl Acad Sci USA. 72:1975;p. 1848–1854
  73. Hwang D. Essential fatty acids and immune response. FASEB J. 1989;3:2052–2061
  74. Taffet SM, Pace JL, Russell SW. Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E2. J Immunol. 1981;127:121–124
  75. Beckerman KP, Schreiber RD, Needleman P. Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. Prosta Leuk Ess Fat Acids. 1992;47:231–238
  76. Polverini PJ. Macrophage-induced angiogenesis: a review. In: Song C editors. Macrophage-derived cell regulatory factors. Cytokines Basel: Karger; 1989;p. 54–73
  77. Nakaguchi K, Nishijima J, Lgawa M, et al. Purification and some properties of membrane-associated phospholipase A2 of human spleen. Enzyme. 1987;35:2–12
  78. Takayama K, Kudo I, Kim DK, et al. Purification and characterization of human platelet phospholipase A2 which preferentially hydrolyzed an arachidonyl residue. FEBS Lett. 1991;282:326–330
  79. Heinrikson RL, Krueger ET, Leim PS. Amino acid sequence of phospholipase A2-Alpha from the venom of Crotalus Adamanteus. A new classification of phospholipase A2 based upon structural determinants. J Biol Chem. 1977;252:4913–4921
  80. Ono T, Tojo H, Kuramitsu S, et al. Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with cytosolic phospholipase A2 S-1. J Biol Chem. 1988;263:5732–5738
  81. Clark JD, Lin LL, Kriz RW, et al. A novel arachidonic acid-selective cytosolic phospholipase A2 contains a Ca(2+) dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043–1051
  82. Seilhamer JJ, Pruzanski W, Vadas P, et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989;264:5335–5338
  83. Yhamashita SI, Ogawa M, Sakamoto K, et al. Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta. 1994;228:91–99
  84. Abe T, Sakamoto K, Kamohara H, et al. Group II phospholipase A2 in increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer. 1997;74:245–250
  85. Wolbink GJ, Schalkwijk C, Baars JW, et al. Therapy with interleukin-2 induces the systemic release of phospholipase A2. Can Immunol Immunother. 1995;41:287–292
  86. Heasley LE, Thaler S, Nicks M, et al. Induction of cytosolic phosphilipase A2 by oncogenic ras in human non-small cell lung cancer. J Biol Chem. 1997;272:14501–14504
  87. Honn KV, Tang DG, Xiang G, et al. I2-lipoxygenases and I2(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 1994;13:365–396
  88. in press Moody TW, Leyton J, Martinez A, et al. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998;
  89. Tang DG, Grossi IM, Tang KQ, et al. Inhibition of TPA and as(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer. 1995;60:418–425
  90. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. In: Proc Natl Acad Sci USA. 93:1996;p. 5241–5246
  91. Sirois J, Levy LO, Simmons DL, Richards JS. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells: Identification of functional and protein binding regions. J Biol Chem. 1993;268:12199–12206
  92. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem. 1992;267:7991–7994
  93. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmac Ther. 1991;49:153–179
  94. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science. 1985;227:1477–1479
  95. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866–12872
  96. Xie W, Herschman HR. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem. 1994;270:27622–27628
  97. Kurchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. In: Proc Natl Acad Sci USA. 93:1996;p. 4816–4820
  98. Kargman SL, O'Neil GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995;55:2556–2559
  99. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med. 1993;328:1313–1316
  100. Thun M, Namboodiri M, Heath C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–1596
  101. Thun M, Namboodiri M, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–1327
  102. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994;154:394–399
  103. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethase-induced colon carcinogenesis in rats with reducing prostaglandin levels. Cancer Res. 1997;57:2909–2915
  104. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57:2452–2459
  105. Hohn KV, Cicone B, Skoff A. Prostacyclin: A potent antimetastatic agent. Science. 1981;212:1270–1272
  106. Schneider MR, Tang DG, Schirner M, et al. Prostacyclin and its analogues: Antimetastic effects and mechanisms of action. Cancer Metastasis Rev. 1994;13:349–364
  107. Schirner M, Schneider MR. Inhibition of metastasis by Cicaprost in rats with established SMTA2 mammary carcinoma growth. Cancer Detec and Preven. 1997;21:44–50
  108. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409–415
  109. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301
  110. Geraci MW, Gao B, Shepherd D, et al. Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice. Chest. 1998;114:99S
  111. Keith RL, Miller YE, Malkinson AM, et al. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of adenocarcinoma: Implications for chemoprevention and gene therapy. In: Sixth SPORE Investigator's Workshop. Rockville, MD, July 12–14. 1998;
  112. Heasley LE, Johnson GL. Signal Transduction Abnormalities in Lung Cancer. In: Kane MA, Bunn PA editor. Lung Biology in Health and Disease: Biology of Lung Cancer. New York: Marcel Dekker; 1998;p. 371–390

PII: S1368-7646(98)80013-7

Drug Resistance Updates
Volume 1, Issue 6 , Pages 377-388 , 1998

Article Tools